<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968953</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16060524</org_study_id>
    <nct_id>NCT02968953</nct_id>
  </id_info>
  <brief_title>Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome</brief_title>
  <official_title>Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Goldstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a
      single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a
      single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome. Patient has already
      tried the other acceptable treatments for GLUT1 with either side effects that caused
      treatment to be discontinued (Ketogenic Diet) or a current treatment that is not showing any
      efficacy and is difficult to sustain for a long duration given this patient's age (modified
      Atkins diet). Due to the patient's ongoing neuroregression and lack of other viable
      treatments, the use of UX007 (triheptanoin) is warranted. There is no comparable or
      satisfactory alternative therapy to treat this patient's severely debilitating condition and
      the potential benefits to the patient justify the potential risks of the treatment. The
      potential risks from UX007 (triheptanoin) are not unreasonable given the context of this
      patient's condition.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of triheptanoin for GLUT1 Deficiency Syndrome</measure>
    <time_frame>Minimum of one year</time_frame>
    <description>Patient visits will be conducted every three months to assess her clinical status and to gather data to determine the efficacy of UX007 (triheptanoin). UX007 (triheptanoin) will be provided to the patient for a minimum of one year to assess efficacy, but treatment will go on indefinitely if it is found to be efficacious for this patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Glucose Transporter 1 Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>UX007 (Triheptanoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UX007 (triheptanoin) will be administered orally at a dose of up to 3 g/kg/day, which is approximately equivalent to 30% of total daily caloric needs, divided into up to four doses per day. The dose of UX007 (triheptanoin) will be adjusted to account for growth, weight gain, tolerability or adverse event(s). The dose may be reduced or UX007 (triheptanoin) may be discontinued, as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin</intervention_name>
    <description>A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).</description>
    <arm_group_label>UX007 (Triheptanoin)</arm_group_label>
    <other_name>UX007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment
             of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.

        Exclusion Criteria:

          -  Not applicable as study only includes one patient.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pascual JM, Liu P, Mao D, Kelly DI, Hernandez A, Sheng M, Good LB, Ma Q, Marin-Valencia I, Zhang X, Park JY, Hynan LS, Stavinoha P, Roe CR, Lu H. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol. 2014 Oct;71(10):1255-65. doi: 10.1001/jamaneurol.2014.1584.</citation>
    <PMID>25110966</PMID>
  </reference>
  <reference>
    <citation>Blumenschine M, Montes J, Rao AK, Engelstad K, De Vivo DC. Analysis of Gait Disturbance in Glut 1 Deficiency Syndrome. J Child Neurol. 2016 Nov;31(13):1483-1488. Epub 2016 Aug 10.</citation>
    <PMID>27511993</PMID>
  </reference>
  <reference>
    <citation>Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, HÃ©ron B, Roubertie A, Kaphan E, Valabregue R, Rinaldi D, Vuillaumier S, Schiffmann R, Ottolenghi C, Hogrel JY, Servais L, Roze E. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016 May;87(5):550-3. doi: 10.1136/jnnp-2015-311475. Epub 2015 Nov 3.</citation>
    <PMID>26536893</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>November 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Amy Goldstein</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
